Achieving Durable Regimentation in Vitiligo Through Novel Targets & New Modalities
Time: 11:20 am
day: Day One AM
Details:
- Vitiligo is an autoimmune disease of the skin with significant unmet medical need
- Vitiligo is driven by immune signaling through IFNg, and therapies that target this pathway show promise as effective new treatments
- Relapse occurs in up to 40% of vitiligo patients after stopping therapy and this is due to autoreactive resident memory T cells that can be targeted by blocking IL-15
- Emerging therapeutic options to target identified pathways that drive disease abound, including small molecules, biologics, and RNA interference
